In 2015, a phase I clinical trial of patients with EpCAM-positive metastatic cancers aimed at evaluating the maximum tolerated doses, pharmacokinetics, and immunogenicity of the anti-EpCAM-based immunotoxin MOC31PE that is coupled to Pseudomonas exotoxin A. MOC31PE was intravenously combined with the immunosuppressant cyclosporin in n = 63 metastatic patients and revealed a safe profile with a half-life in plasma of 3 h and a reduction of [127]. The gene discussed is EPCAM; the disease is metastatic malignant neoplasm.